Sanofi SA (NYSE:SNY) – Investment analysts at Jefferies Group upped their FY2017 earnings per share estimates for shares of Sanofi in a research note issued on Tuesday. Jefferies Group analyst J. Holford now anticipates that the company will post earnings per share of $3.45 for the year, up from their previous estimate of $3.18. Jefferies Group also issued estimates for Sanofi’s FY2018 earnings at $3.42 EPS and FY2022 earnings at $4.75 EPS.
Several other research firms have also issued reports on SNY. UBS Group reissued a “neutral” rating on shares of Sanofi in a research report on Monday. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a research report on Thursday, January 11th. Nord/LB reissued a “neutral” rating on shares of Sanofi in a research report on Tuesday, January 2nd. Cowen set a $48.00 price objective on shares of Sanofi and gave the stock a “hold” rating in a research report on Monday, December 18th. Finally, Bank of America lowered shares of Sanofi from a “buy” rating to a “neutral” rating in a research report on Wednesday, December 6th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $51.50.
Sanofi (NYSE SNY) opened at $44.60 on Wednesday. Sanofi has a 52-week low of $39.42 and a 52-week high of $50.65. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.16 and a current ratio of 1.59. The company has a market cap of $113,200.00, a P/E ratio of 20.18, a P/E/G ratio of 2.58 and a beta of 0.86.
Sanofi (NYSE:SNY) last issued its quarterly earnings results on Thursday, November 2nd. The company reported $1.00 EPS for the quarter, hitting the consensus estimate of $1.00. Sanofi had a net margin of 25.44% and a return on equity of 25.19%.
Several institutional investors have recently added to or reduced their stakes in SNY. Southpoint Capital Advisors LP acquired a new stake in shares of Sanofi in the second quarter worth $57,492,000. BlackRock Inc. increased its position in shares of Sanofi by 47.6% in the second quarter. BlackRock Inc. now owns 2,235,422 shares of the company’s stock worth $107,100,000 after acquiring an additional 720,523 shares in the last quarter. Boston Partners increased its position in shares of Sanofi by 6.2% in the third quarter. Boston Partners now owns 8,664,983 shares of the company’s stock worth $431,429,000 after acquiring an additional 503,799 shares in the last quarter. Janus Henderson Group PLC acquired a new stake in Sanofi during the 2nd quarter valued at $22,558,000. Finally, Fisher Asset Management LLC grew its holdings in Sanofi by 3.3% during the 3rd quarter. Fisher Asset Management LLC now owns 14,082,257 shares of the company’s stock valued at $701,156,000 after purchasing an additional 443,799 shares in the last quarter. 9.08% of the stock is owned by institutional investors.
WARNING: “Sanofi SA (SNY) Forecasted to Earn FY2017 Earnings of $3.45 Per Share” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/18/sanofi-sa-sny-forecasted-to-earn-fy2017-earnings-of-3-45-per-share.html.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.